Evidence map›Paper›PMID 41222991›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

Streamlining the Histopathologic Workflow in Diabetic Kidney Disease with Artificial Intelligence.

Christos Matsoukas, Tajana Tesan Tomic, Pernilla Tonelius, Esther Nuñez-Duran, Lihuan Liang, Annika Wernerson, Johan Mölne, Robert I Menzies, Anna B Granqvist, Pernille B L Hansen and 2 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christos MatsoukasPathology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-1401-3497
Tajana Tesan TomicBioscience Technology, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Pernilla ToneliusBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Esther Nuñez-DuranBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Lihuan LiangBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Annika WernersonDepartment of Clinical Science, Intervention and Technology (CLINTEC), Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.
Johan MölneDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Robert I MenziesBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Anna B GranqvistBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Pernille B L HansenBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kevin SmithKTH Royal Institute of Technology, Stockholm, Sweden.
Magnus SöderbergPathology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-0946-5202

Funding

Wallenberg AI, Autonomous Systems and Software Program
6 · The paper itself

Abstract

key pointsArtificial intelligence models effectively generalized across studies and animal models and reduced translational gaps when applied to human biopsies. Artificial intelligence assistance reduced study evaluation turnaround times by up to 90% versus manual whole slide imaging scoring, matching expert-level performance. Self-supervised learning captured diabetic kidney disease-relevant features and mitigated expert-specific bias.

backgroundAssessment of pathology end points in animal models of diabetic kidney disease is time-consuming and prone to expert bias. In addition, the sparsity of human kidney biopsy data hinders the development of translational models from animals to humans.

methodsWe developed an artificial intelligence (AI)-driven workflow to streamline histopathologic assessments in animal models of diabetic nephropathy. Our approach ( 1 ) detected glomeruli in whole slide images, ( 2 ) enabled fast expert scoring through an annotation tool, and ( 3 ) automated scoring. By leveraging unlabeled preclinical data for self-supervised learning, we enhanced AI scoring performance, reduced expert bias, and enabled the translation of AI scoring from animal models to human biopsies. To translate AI models from preclinical studies to human biopsies, we introduced a method that adjusted the feature extractor to human-specific features during inference without the need for annotated examples.

resultsOur annotation tool streamlined glomerular scoring, reducing turnaround time by 80%. Supervised AI models outperformed expert agreement and further reduced turnaround time by 90%, demonstrating generalization across studies involving both the same and different animal models. Without supervision, the self-supervised model achieved a κ value of 0.78, effectively identifying glomerular changes without guidance. Incorporating self-supervised learning into supervised training improved performance to κ=0.84 and reduced bias compared with individual experts ( P < 0.001). Our translational approach achieved a κ value of 0.63 on human glomeruli, although the model was trained exclusively on mouse glomeruli scores, reducing the translational gap by 45%.

conclusionsIn this study, we accelerated and enhanced pathology readouts in a real-life pharmaceutical industry setting. We show that AI-assisted scoring reduced pathologists' workload and expedited study assessments. Self-supervised learning captured intrinsic properties of kidney morphology without expert annotation and reduced expert bias and translational discrepancies, greatly facilitating translational activities in drug development for patients with diabetic kidney disease.

Indexed as

Artificial IntelligenceDiabetic NephropathiesWorkflowAnimalsBiopsyDisease Models, AnimalHumansKidney GlomerulusMiceSupervised Machine LearningCKDdiabetic kidney diseaseglomerular diseasesglomerulus

Identifiers

PMID41222991
PMCPMC13143442

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.